Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Executive Summary

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Advertisement

Related Content

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'
Parallel Trade Adds Up As Abacus Prepares IPO
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule
Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased
Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines
Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?
Emergings In Brief, May 2013
Marinomed Biotechnologie GMBH

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124180

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel